Complix Receives €1.9 Million IWT Grant to Accelerate Development Of Alphabodies™ against Intracellular Disease Targets, Including Cancer

Informations

• Publié par: complix
• Nombre de lectures: 12
• Langue: English

Extrait

Complix Receives €1.9 Million IWT Grant to Accelerate Development Of Alphabodies™ against Intracellular Disease Targets, Including Cancer

PR Newswire HASSELT, Belgium, October 30, 2012

HASSELT, Belgium,October 30, 2012/PRNewswire/ --

Complix announces that it has been awarded a €1.9 m illion grant (approximatelyUSD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). The grant will allow Complix to accelerate the developm ent of its unique cell penetrating Alphabodies (CPA Bs), against a range of intracellular disease targets, including cancer.

Alphabodies represent a novel therapeutic development platform with the potential to address a vast number of disease targets that are currently considered "undruggable" by the two main classes of therapeutic drugs: small chemical drugs and therapeutic antibodies. In particular their ability to act on intracellular protein targets represents a major medical and commercial opportunity.

During the past year, Complix has generated a wealth of data demonstrating the attractive properties of CPABs that are capable of acting on intracellular disease targets. These results show that CPABs are taken up effectively by tumor cells. Once inside cancer cells the CPABs can act on an oncogenic target protein and block its function, thereby inducing apoptosis (cell death).

Dr Mark Vaeck, CEO of Complix, said: "We are delighted to have received this funding from IWT, which is a clear endorsement of the power of our unique CPAB platform. The results that we have generated so far indicate this platform has the potential to transform the pharmaceutical industry's ability to address the most interesting class of potential drug targets, namely intracellular protein-protein interactions (PPIs).

"Although intracellular PPIs are known to be involved in a variety of important disease processes, such as cancer, autoimmunity, CNS and metabolic diseases, most of them have been found intractable by small chemicals or antibodies. Whilst other new technology platforms are currently also attempting to address this opportunity, we believe that Complix is well positioned to become a leading player in this next generation of so called "cross-over therapeutics", which have the potential to boost future R&D pipelines and revitalize the growth of the pharmaceutical industry."

Alphabodies are small single chain alpha-helical proteins that are designed by computer modeling, but are inspired by naturally existing polypeptide structures. Alphabodies can address a diverse range of traditionally undruggable disease targets and combine the best beneficial properties of biologics and small chemical drugs, such as high specificity and potency on large protein targets, w ith efficient intracellular penetration and excellent stability in human serum.

Alphabodies also have the potential to be applied in other fields beyond the treatment of human disease. Complix recently announced an important value-generating partnership with Monsanto Company that will apply Com plix' Alphabodies to create novel products for agricultural applications.

About Complix

Complix discovers and develops Alphabodies, a novel and proprietary class of biopharmaceuticals that delivers significant advantages over current protein therapeutic approaches. Alphabodies' most important advantage is their ability to address currently undruggable extracellular and, in particular, intracellular targets.

Complix is developing cell penetrating Alphabodies (CPABs) that have the potential to modulate intracellular PPIs, and has generated data demonstrating that CPABs are able to enter cells, bind to disease targets and can generate biological effects at low concentrations. CPABs have been designed to tackle the significant proportion of all known human disease targets that are located inside cells and cannot be addressed by either small chemical drugs or biologics. These targets belong to the most interesting class of potential drug targets, namely intracellular protein- protein interactions (PPIs), which are involved in important disease processes, such as those causing cancer, CNS, inflammation or metabolic diseases.

Alphabodies are composed of structurally constrained alpha-helical peptide coils, which make them ideal scaffolds for therapeutic applications as they combine the specificity of antibodies with small molecule-like properties. Alphabodies' unique design, which has been invented by the Complix founders, means that the Company has a unique freedom-to-operate position. Complix has already established a strong intellectual property position for its Alphabody platform through the filing of several broad patent applications.

Complix´s current R&D focus is on the development of novel Alphabody-based therapies for inflammation/autoimmunity and cancer.

Complix raisedEUR 7 millionthrough a Series A equity financing round in 2010, with Vesalius Biocapital, LRM and Crédit Agricole Private Equity (currently Omnes Capital) as the main investors.

Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully owned subsidiary inLuxembourg and a strategic alliance with the public research institute CRP-Santé. For further information, please visithttp://www.complix.com.

Contacts Complix NV Dr. Mark Vaeck, CEO [phone]